Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Authors
Keywords
Driver mutations, Non-driver mutations, Myelofibrosis, Essential thrombocythemia, Polycythemia vera, JAK2 inhibitors, Ruxolitinib
Journal
MEDICAL ONCOLOGY
Volume 35, Issue 9, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-03
DOI
10.1007/s12032-018-1187-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study
- (2018) J. Mascarenhas et al. ANNALS OF HEMATOLOGY
- Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
- (2018) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The role of JAK2 inhibitors in MPNs 7 years after approval
- (2018) Francesco Passamonti et al. BLOOD
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- (2018) Hans Michael Kvasnicka et al. Journal of Hematology & Oncology
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2017) C N Harrison et al. LEUKEMIA
- A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
- (2017) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Mutations in myeloproliferative neoplasms – their significance and clinical use
- (2017) Fiorella Schischlik et al. Expert Review of Hematology
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
- (2016) Mohamed Shanavas et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
- (2015) C. Marty et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
- (2015) D Pietra et al. LEUKEMIA
- Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest
- (2015) Julie Mondet et al. MEDIATORS OF INFLAMMATION
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
- (2014) Matteo Molica et al. ANNALS OF HEMATOLOGY
- Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
- (2014) P. Guglielmelli et al. BLOOD
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- The JAK2 exon 12 mutations: A comprehensive review
- (2011) Linda M. Scott AMERICAN JOURNAL OF HEMATOLOGY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor
- (2009) C. Pecquet et al. BLOOD
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now